[Therapeutic efficacy of a new antirheumatic agent with optimal gastrointestinal tolerance: 2-phenyl-4,p-chlorophenyl-thiazol-5-ilacetic acid (Fentiazac)].
D000085:Acetates / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004361:Drug Tolerance; D006801:Humans; D008297:Male; D008875:Middle Aged; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013270:Stomach / Q000187:drug effects; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*
D000085:Acetates; D000893:Anti-Inflammatory Agents; D013844:Thiazoles
Indogini sull'efficacia terapeutica di un nuovo farmaco anti-reumatico ad ottina tollerabilita' gastrointestinale: ac. 2-fenil-4, p-clorofenil-tiazol-5-ilacetico (Fentiazac)